China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Down 29.1% in February

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 52,570 shares, a drop of 29.1% from the February 12th total of 74,183 shares. Based on an average trading volume of 72,335 shares, the short-interest ratio is currently 0.7 days. Approximately 5.7% of the company’s shares are short sold. Approximately 5.7% of the company’s shares are short sold. Based on an average trading volume of 72,335 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, China SXT Pharmaceuticals has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Down 11.3%

Shares of NASDAQ SXTC opened at $1.89 on Monday. China SXT Pharmaceuticals has a twelve month low of $1.88 and a twelve month high of $1,046.98. The stock has a fifty day simple moving average of $26.08 and a 200-day simple moving average of $155.85.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in China SXT Pharmaceuticals during the 4th quarter worth approximately $36,000. Citadel Advisors LLC purchased a new position in China SXT Pharmaceuticals in the 3rd quarter valued at approximately $78,000. Finally, Virtu Financial LLC grew its stake in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after acquiring an additional 15,013 shares in the last quarter. Hedge funds and other institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.